The Next Wave Of M&A Sweeps In, Bringing Novel Approaches That May Be Here To Stay
Executive Summary
The first half of 2014 has been one wild M&A ride for the pharma industry, with some of the most valuable deals pharma has seen in years proposed. They have involved everything from asset swaps to mega-mergers, activist investors and tax inversion strategies, suggesting industry is testing different approaches to address a similar challenge: increasing pressure from payers to reduce health care and drug spending.